Prelude Therapeutics presents preclinical data for PRT13722 KAT6A degrader at AACR 2026, plans IND mid-2026

Prelude Therapeutics Inc

PRT13722 is a first-in-class, orally bioavailable, potent and highly selective KAT6A degrader for HR+/HER2- breast cancer.
Preclinical data show durable complete tumor regressions in xenograft models at well-tolerated doses as monotherapy.
PRT13722 demonstrated improved preclinical hematological safety profile compared to prifetrastat.
PRT13722 showed synergistic activity with endocrine therapy, CDK4/6 inhibitors, and PI3Kα inhibitors.
IND filing expected in mid-2026; Phase 1 study initiation planned for second half of 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.